Previous 10 | Next 10 |
Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma Data suggests that ctDNA dynamics may be a better surrogate of overall survival than radiographic imaging (RECIST criteria) PR Newswire AUSTIN, Texas , Sept. 17, 2021 ...
Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quan...
Healthcare had a slow start but now is one of the leading sectors in terms of 2021 performance. Healthcare is well-positioned to benefit from growing spending and pent-up demand. The sector is also a defensive investment if economic growth concerns mount. Regulatory risk remai...
Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer Pivotal clinical trial aims to establish a new standard of care for stage II and III colon cancer patients PR Newswire AUSTIN,...
The precipitous cost decline of next-generation DNA sequencing has supercharged our understanding of tumor biology. The strange biology that makes it dangerous also gives scientists the opportunity to detect cancer earlier. The exponential cost declines associated with NGS, AI, an...
Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test Prospera Heart identifies rejection with exceptional performance from a single test, eliminating the need to combine two tests for each patient PR Newswire AUSTIN, T...
The following slide deck was published by Natera, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Natera, Inc. 2021 Q2 - Results - Earnings Call Presentation
Natera, Inc. (NTRA) Q2 2021 Earnings Conference Call August 5, 2021 04:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - JPMorgan Catherine Schulte - Baird ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Illumina’s (NASDAQ: ILMN ) strong growth and tremendous potential make ILMN stock worth buying. Source: Shutterstock It’s true that the company’s shares are not at all cheap. Still, the dema...
Natera (NASDAQ:NTRA): Q2 GAAP EPS of -$1.32 misses by $0.20. Revenue of $142.03M (+64.3% Y/Y) beats by $11.16M. Press Release For further details see: Natera EPS misses by $0.20, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...